Article info
PDFEpidemiology
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases
- Correspondence to Dr Robert Biesen, Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Berlin, Germany; robert.biesen{at}charite.de
Citation
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases
Publication history
- Received November 17, 2021
- Accepted February 24, 2022
- First published March 14, 2022.
Online issue publication
May 16, 2022
Article Versions
- Previous version (14 March 2022).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.